Imiquimod, a toll-like receptor 7 (TLR7) agonist, induces skin inflammation resembling human psoriasis via activation of the interleukin 23 (IL-23)/interleukin 17 (IL-17) axis [4, 5]. This evidence concerns the gene IL37 and psoriasis.